
Contractility is the intrinsic ability of the heart muscle to generate force and shorten. The force-frequency relation can reveal initial alterations between normal and abnormal contractility, making it a practical index for clinical evaluation. This narrative review provides a picture of force-frequency relationship assessment, including stress echocardiography laboratories (echo labs), nuclear laboratories (nuclear labs), implantable systems, ambulatory sensors, and wearable sensors. Different approaches have been investigated in the literature, and their translation into practice could be valuable, even if challenging. With a vision for the future, real-time monitoring systems based on wearable or implantable devices, able to continuously track force-frequency changes during daily activities, could constitute a concrete opportunity for improved management of conditions such as chronic heart failure and coronary artery disease.
BACKGROUND Durable mechanical circulatory support with a left ventricular assist device (LVAD) serves as bridge to heart transplantation (HTx) in patients with advanced heart failure. LVAD therapy is associated with improved outcomes, but has inherent limitations, including device-related complications. In this study, we aimed to evaluate the impact of prolonged LVAD support in patients who underwent HTx as compared to those without LVAD support. METHOD We retrospectively analysed 148 HTx recipients at University Medical Center Groningen, the Netherlands (2007-2023): 52 with prior LVAD support and 96 direct HTx patients. Outcomes included post-HTx survival, rejection requiring treatment, 1-year cardiac haemodynamics, and need for kidney replacement therapy. RESULTS Median LVAD duration was 757 days (range 16-2,113). The LVAD group had fewer females (21% vs 54%; p<0.001). After a median 3.5-year follow-up, post-HTx survival was similar between groups (hazard ratio 0.83; 95% confidence interval 0.40-1.6; p=0.52). No significant differences were observed in the incidence of rejection requiring therapy (p=0.91) nor need for kidney replacement therapy (p=0.05-0.42). At 1-year post-HTx, the LVAD group showed modestly elevated pulmonary capillary wedge pressure (12.7 vs 10.6 mmHg; p=0.03) and reduced cardiac index (3.0 vs 3.3 L/min/m2; p=0.03) compared to direct HTx recipients. CONCLUSIONS Prolonged LVAD support as bridge-to-transplantation showed no statistically significant differences with direct HTx in terms of post-HTx survival, rejection rates, and renal function despite minor differences in 1-year haemodynamic parameters.